{
  "id": 19062435,
  "title": "StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate",
  "url": "https://urgent.news/2026/11/09/stockwatch-nurix-nosedives-as-sanofi-halts-phase-i-immunology",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-09T01:26:46.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/translational-medicine/stockwatch-nurix-nosedives-as-sanofi-halts-phase-i-immunology-candidate/"
  },
  "original_language": "en",
  "account": "Nurix Therapeutics experienced its largest single-day drop as a public entity on Wednesday when Sanofi halted development of their jointly developed Phase I immunology candidate, SAR448272 (NX-3911). Despite Sanofi's termination of SAR448272, the collaboration between the two companies will continue. The termination of the program, which was under study in a first-in-human trial in Europe, triggered a $10 million payment from Sanofi to Nurix in August. Nurix had secured $1.1 billion in cash, cash equivalents, and marketable securities as of August 31. While Nurix's executives stated that their cash runway would remain unaffected, their stock price suffered a 38% decrease from $25.82 to $15.95 following the news. However, the stock recovered slightly by Friday, closing the week at $15.30, marking a nearly 43% decline over five days. Analysts noted that while Nurix's stock experienced a significant drop, the company remains in a strong position with three clinical-stage programs and an exciting preclinical pipeline. Nurix is currently in a strategic inflection point with a potential $48 billion addressable market opportunity in five diseases, including chronic lymphocytic leukemia (CLL) and multiple sclerosis (MS).",
  "summary": "Sanofi halted development of an oral STAT6 degrader that had been under study in a Phase I first-in-human trial in Europe. STAT6, a key drug target in type 2 inflammation, is among the five targets identified by the companies in their collaboration, launched in 2020. The post StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate appeared first on GEN - Genetic Engineering and…",
  "key_points": [
    "Nurix Therapeutics stock drops 38% after Sanofi halts Phase I immunology candidate SAR448272.",
    "$10 million payment from Sanofi to Nurix triggered by termination of jointly developed program."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}